Personalized Cancer Vaccine NEO-PV-01 Shows Promise in 3 Types of Advanced Cancer
Source: Cancer Therapy Advisor, August 2019
New results released by Neon Therapeutics1 have shown promising, early results for their NEO-PV-01 personalized neoantigen vaccine in combination with nivolumab across 3 different types of advanced cancer.
In May 2019, Cancer Therapy Advisor reported on results presented at the 2019 American Association for Cancer Research (AACR) Annual Meeting of NEO-PV-01 in a small cohort of 23 patients with advanced melanoma.2 The new report shows 12-month median follow-up outcomes in 82 patients with advanced melanoma, smoking-associated non-small cell lung cancer (NSCLC), or advanced bladder cancer.
In all 3 cancer types, progression-free survival (PFS) was favorable compared with historical results in these cancer types with just nivolumab treatment alone.
“Collectively, these data demonstrate a promising new approach in the field of cancer immunotherapy with the potential to further broaden and extend the benefits of checkpoint inhibitor treatment to improve patient outcomes in multiple cancer settings,” said Patrick Ott, MD, PhD, clinical director of the melanoma center, center for immuno-oncology at Dana-Faber Cancer Institute, Boston, Massachusetts, and a lead investigator in the NT-001 trial.